RT Journal Article
SR Electronic
T1 SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.20.21259195
DO 10.1101/2021.06.20.21259195
A1 Bolze, Alexandre
A1 Cirulli, Elizabeth T.
A1 Luo, Shishi
A1 White, Simon
A1 Wyman, Dana
A1 Rossi, Andrew Dei
A1 Machado, Henrique
A1 Cassens, Tyler
A1 Jacobs, Sharoni
A1 Schiabor Barrett, Kelly M.
A1 Tsan, Kevin
A1 Nguyen, Jason
A1 Ramirez, Jimmy M.
A1 Sandoval, Efren
A1 Wang, Xueqing
A1 Wong, David
A1 Becker, David
A1 Laurent, Marc
A1 Lu, James T.
A1 Isaksson, Magnus
A1 Washington, Nicole L.
A1 Lee, William
YR 2021
UL http://medrxiv.org/content/early/2021/07/30/2021.06.20.21259195.abstract
AB This study reports on the displacement of Alpha (B.1.1.7) by Delta (B.1.617.2 and its substrains AY.1, AY.2, and AY.3) in the United States. By analyzing RT-qPCR testing results and viral sequencing results of samples collected across the United States, we show that the percentage of SARS-CoV-2 positive cases caused by Alpha dropped from 67% in May 2021 to less than 3.0% in just 10 weeks. We also show that the Delta variant has outcompeted the Iota (B.1.526) variant of interest and Gamma (P.1) variant of concern. An analysis of the mean quantification cycles (Cq) values in positive tests over time also reveal that Delta infections lead to a higher viral load on average compared to Alpha infections, but this increase is only 2 to 3x on average for our study design. Our results are consistent with the hypothesis that the Delta variant is more transmissible than the Alpha variant, and that this could be due to the Delta variant’s ability to establish a higher viral load earlier in the infection compared to the Alpha variant.Competing Interest StatementA.B., E.T.C., S.L., S.W., D.W., A.D.R., H.M., T.C., S.J., K.M.S.B., K.T., J.N., J.M.R., E.S., X.W., D.W., D.B., M.L., J.T.L., M.I., N.L.W. and W.L. are employees of Helix.Funding StatementThis work has been funded in part by CDC BAA contracts 75D30121P10258 (Illumina, Helix). This work was also funded in part by Helix internal funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this manuscript are available from the Data tables in supplementary material. It can also be accessed on Helix Github COVID page: https://github.com/myhelix/helix-covid19db. Sequences are also available on GISAID. https://github.com/myhelix/helix-covid19db